Impact of malignancy on Clostridium difficile infection

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 35, Issue 11, 2016, Pages 1771-1776

  Chung, M S ^a   Kim, J ^a   Kang, J O ^a   Pai, H ^a  

^a Hanyang University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC METAL COMPLEX; DNA TOPOISOMERASE INHIBITOR; FLUOROURACIL; FLUOROURACIL DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; FEMALE; FEMALE GENITAL TRACT CANCER; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HOSPITALIZATION; HUMAN; HUMAN CELL; LEUKOCYTOSIS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NEOPLASM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; SENESCENCE; URINARY TRACT CANCER; CLOSTRIDIUM INFECTIONS; COMPLICATION; DRUG THERAPY; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; NEOPLASMS; PEPTOCLOSTRIDIUM DIFFICILE; PROCEDURES; RECURRENT DISEASE; RETROSPECTIVE STUDY;

AGED; ANTINEOPLASTIC AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DRUG THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 84979710762     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-016-2725-6     Document Type: Article

References (33)

1. Kelly CP, LaMont JT (2008) Clostridium difficile—more difficult than ever. N Engl J Med 359(18):1932–1940. doi:10.1056/NEJMra0707500
2. Monge D, Millan I, Gonzalez-Escalada A, Asensio A (2013) The effect of Clostridium difficile infection on length of hospital stay. A cohort study. Enferm Infecc Microbiol Clin 31(10):660–664. doi:10.1016/j.eimc.2012.11.007
3. McFarland LV, Mulligan ME, Kwok RY, Stamm WE (1989) Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 320(4):204–210. doi:10.1056/NEJM198901263200402
4. Bartlett JG, Gerding DN (2008) Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 46(Suppl 1):S12–S18. doi:10.1086/521863
5. Kamthan AG, Bruckner HW, Hirschman SZ, Agus SG (1992) Clostridium difficile diarrhea induced by cancer chemotherapy. Arch Intern Med 152(8):1715–1717
6. Husain A, Aptaker L, Spriggs DR, Barakat RR (1998) Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens. Gynecol Oncol 71(1):104–107. doi:10.1006/gyno.1998.5158
7. Khan A, Raza S, Batul SA, Khan M, Aksoy T, Baig MA, Berger BJ (2012) The evolution of Clostridium difficile infection in cancer patients: epidemiology, pathophysiology, and guidelines for prevention and management. Recent Patents Anti-infective Drug Discovery 7(2):157–170
8. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B (2012) Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 380(9836):37–43. doi:10.1016/S0140-6736(12)60240-2
9. Rodriguez Garzotto A, Merida Garcia A, Munoz Unceta N, Galera Lopez MM, Orellana-Miguel MA, Diaz-Garcia CV, Cortijo-Cascajares S, Cortes-Funes H, Agullo-Ortuno MT (2015) Risk factors associated with Clostridium difficile infection in adult oncology patients. Supportive Care Cancer: Off J Multinational Assoc Support Care Cancer 23(6):1569–1577. doi:10.1007/s00520-014-2506-7
10. Yoon YK, Kim MJ, Sohn JW, Kim HS, Choi YJ, Kim JS, Kim ST, Park KH, Kim SJ, Kim BS, Shin SW, Kim YH, Park Y (2014) Predictors of mortality attributable to Clostridium difficile infection in patients with underlying malignancy. Supportive Care Cancer: Off J Multinational Assoc Supportive Care Cancer 22(8):2039–2048. doi:10.1007/s00520-014-2174-7
11. Krishna SG, Zhao W, Apewokin SK, Krishna K, Chepyala P, Anaissie EJ (2013) Risk factors, preemptive therapy, and antiperistaltic agents for Clostridium difficile infection in cancer patients. Transplant Infect Dis 15(5):493–501. doi:10.1111/tid.12112
12. Hwang KE, Hwang YR, Seol CH, Park C, Park SH, Yoon KH, Park DS, Lee MK, Jeong ET, Kim HR (2013) Clostridium difficile Infection in lung cancer patients. Jpn J Infect Dis 66(5):379–382
13. Gravel D, Miller M, Simor A, Taylor G, Gardam M, McGeer A, Hutchinson J, Moore D, Kelly S, Boyd D, Mulvey M, Canadian Nosocomial Infection Surveillance P (2009) Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. Clinical Infect Dis 48(5):568–576. doi:10.1086/596703
14. Barbut F, Richard A, Hamadi K, Chomette V, Burghoffer B, Petit JC (2000) Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 38(6):2386–2388
15. Kuijper EJ, Coignard B, Tull P (2006) Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 12(Suppl 6):2–18. doi:10.1111/j.1469-0691.2006.01580.x
16. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB (2007) A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45(3):302–307. doi:10.1086/519265
17. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH (2010) Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 31(5):431–455. doi:10.1086/651706
18. O’Connor JR, Johnson S, Gerding DN (2009) Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 136(6):1913–1924. doi:10.1053/j.gastro.2009.02.073
19. Aspinall ST, Hutchinson DN (1992) New selective medium for isolating Clostridium difficile from faeces. J Clin Pathol 45(9):812–814
20. Persson S, Torpdahl M, Olsen KE (2008) New multiplex PCR method for the detection of Clostridium difficile toxin A (tcdA) and toxin B (tcdB) and the binary toxin (cdtA/cdtB) genes applied to a Danish strain collection. Clin Microbiol Infect 14(11):1057–1064. doi:10.1111/j.1469-0691.2008.02092.x
21. Bidet P, Barbut F, Lalande V, Burghoffer B, Petit JC (1999) Development of a new PCR-ribotyping method for Clostridium difficile based on ribosomal RNA gene sequencing. FEMS Microbiol Lett 175(2):261–266
22. Chopra T, Alangaden GJ, Chandrasekar P (2010) Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients. Expert Rev Anti-Infect Ther 8(10):1113–1119. doi:10.1586/eri.10.95
23. Maroo S, Lamont JT (2006) Recurrent clostridium difficile. Gastroenterology 130(4):1311–1316. doi:10.1053/j.gastro.2006.02.044
24. Garey KW, Sethi S, Yadav Y, DuPont HL (2008) Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 70(4):298–304. doi:10.1016/j.jhin.2008.08.012
25. Marsh JW, Arora R, Schlackman JL, Shutt KA, Curry SR, Harrison LH (2012) Association of relapse of Clostridium difficile disease with BI/NAP1/027. J Clin Microbiol 50(12):4078–4082. doi:10.1128/jcm.02291-12
26. Kim J, Pai H, Seo MR, Kang JO (2011) Epidemiology and clinical characteristics of Clostridium difficile infection in a Korean tertiary hospital. J Korean Med Sci 26(10):1258–1264. doi:10.3346/jkms.2011.26.10.1258
27. Lee JH, Lee SY, Kim YS, Park SW, Park SW, Jo SY, Ryu SH, Lee JH, Moon JS, Whang DH, Shin BM (2010) The incidence and clinical features of Clostridium difficile infection; single center study. Kor J Gastroenterol (Taehan Sohwagi Hakhoe Chi) 55(3):175–182
28. Johnson S (2009) Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 58(6):403–410. doi:10.1016/j.jinf.2009.03.010
29. Kelly CP (2012) Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect 18(Suppl 6):21–27. doi:10.1111/1469-0691.12046
30. Bishop KD, Castillo JJ (2012) Risk factors associated with Clostridium difficile infection in adult oncology patients with a history of recent hospitalization for febrile neutropenia. Leuk Lymphoma 53(8):1617–1619. doi:10.3109/10428194.2012.654472
31. Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, Turgeon N, Toye B, Beaudoin A, Frost EH, Gilca R, Brassard P, Dendukuri N, Beliveau C, Oughton M, Brukner I, Dascal A (2011) Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 365(18):1693–1703. doi:10.1056/NEJMoa1012413
32. Kim J, Kang JO, Kim H, Seo MR, Choi TY, Pai H, Kuijper EJ, Sanders I, Fawley W (2013) Epidemiology of Clostridium difficile infections in a tertiary-care hospital in Korea. Clin Microbiol Infect 19(6):521–527. doi:10.1111/j.1469-0691.2012.03910.x
33. Kim J, Seo MR, Kang JO, Kim Y, Hong SP, Pai H (2014) Clinical characteristics of relapses and re-infections in Clostridium difficile infection. Clin Microbiol Infect 20(11):1198–1204. doi:10.1111/1469-0691.12704